A lot of doctors, patients, clinics or hospitals would need to import the unapproved medicine and there have a lot necessary demand to import the Iclusig (ponatinib) under named patient program or clinical trial.\u00a0 The purpose could help those identity to import this product is only available by compassionate use or clinical trial basis.<\/p>\n
If anyone is need this products urgently, you are welcome to contact us and enquire the procedures to import this products.\u00a0 Please note, we are not available to import this product for anyone without the notifications from healthcare professional- doctors, clinic or hospitals where is located in Hong Kong.<\/p>\n
The testimony from China would not be accept, due to the regulation in China PRC.<\/p>\n
Please note, Iclusig (ponatinib) is oncology medicines and the U.S. Food and Drug Administration approved on December 14, 2012 Iclusig (ponatinib) developed and marketed by ARIAD Pharmaceuticals.\u00a0 The indications and clinical use of Iclusig (Ponatinib) is\u00a0 leukemia drug for treatment of chronic myeloid leukemia (the initial is CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), the bone marrow diseases and two rare blood.<\/p>\n
Please make sure all buyers should understand the purpose to use this drugs, and to understand the dosage of this products.\u00a0 Otherwise it would have an negative effect.
\nTrackcircle.com is a coordinator to help the necessary parties to search and import the necessary products, and we are not an organization of healthcare professional.\u00a0 Please consult to your doctors before you use the products.z<\/p>\n","protected":false},"excerpt":{"rendered":"
A lot of doctors, patients, clinics or hospitals would need to import the unapproved medicine and there have a lot necessary demand to import the Iclusig (ponatinib) under named patient program or clinical trial.\u00a0 The purpose could help those identity to import this product is only available by compassionate use or clinical trial basis. If […]<\/p>\n","protected":false},"author":1,"featured_media":747,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[31],"tags":[],"class_list":["post-845","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-31"],"_links":{"self":[{"href":"https:\/\/trackcircle.com\/zh-hans\/wp-json\/wp\/v2\/posts\/845","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trackcircle.com\/zh-hans\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trackcircle.com\/zh-hans\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trackcircle.com\/zh-hans\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/trackcircle.com\/zh-hans\/wp-json\/wp\/v2\/comments?post=845"}],"version-history":[{"count":1,"href":"https:\/\/trackcircle.com\/zh-hans\/wp-json\/wp\/v2\/posts\/845\/revisions"}],"predecessor-version":[{"id":861,"href":"https:\/\/trackcircle.com\/zh-hans\/wp-json\/wp\/v2\/posts\/845\/revisions\/861"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trackcircle.com\/zh-hans\/wp-json\/wp\/v2\/media\/747"}],"wp:attachment":[{"href":"https:\/\/trackcircle.com\/zh-hans\/wp-json\/wp\/v2\/media?parent=845"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trackcircle.com\/zh-hans\/wp-json\/wp\/v2\/categories?post=845"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trackcircle.com\/zh-hans\/wp-json\/wp\/v2\/tags?post=845"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}